Introgen Therapeutics (NASDAQ: INGN) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. We are developing product candidates to treat a wide range of cancers using tumor suppressors, cytokines and other targeted molecular agents. Our products are designed to increase production of normal cancer-fighting proteins that act to overpower cancerous cells, stimulate immune activity, or directly kill cancer cells. Introgen’s therapies can be used alone, but also enhance conventional cancer therapies such as surgery, chemotherapy, radiation and monoclonal antibodies.
Our drug discovery and development programs have resulted in innovative approaches by which physicians may use targeted molecular agents to more precisely treat cancer. Introgen’s low-toxicity approach to cancer treatment has drawn global interest from oncologists.
Introgen’s development program includes five clinical-stage product candidates. Two of the Company's products, ADVEXIN® and INGN 241 are in Phase 3 clinical trials. INGN 225, a therapeutic p53 vaccine, is in Phase 1-2 clinical development for lung and breast cancer. INGN 234, a topical formulation for oral cancer prevention and treatment of oral pre-malignancies, is in Phase 1-2 clinical development. INGN 401, a systemic nanoparticle tumor suppressor is in Phase 1-2 clinical trials for metastatic lung cancer. Introgen’s products have been used in more than 30 worldwide clinical studies involving hundreds of patients.
In June 2008 Introgen submitted a Biologics License Application to the U.S. Food and Drug Administration requesting marketing approval for ADVEXIN p53 therapy to treat recurrent, refractory head and neck cancer. Also in June, Gendux Molecular Limited, an Introgen subsidiary, submitted a Marketing Authorization Application to the European Medicines Evaluation Agency for the same indication.
Introgen also controls a broad intellectual property portfolio that includes more than 400 patent applications and issued patents for a variety of molecular therapy technologies and adenovirus production, purification and formulation. The Company actively collaborates with numerous academic centers of excellence and biotechnology industry partners.
